An interventional study of Three-stage CGM integration program and One-time clinic-based CGM training in Insulin Dependent Diabetes, Diabetes (DM) and Diabetes (Insulin-requiring, Type 1 or Type 2), sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 244th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 614 with no phase, reaches primary completion later than 187 of the 256 other live ones, and was the 1,423rd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Wayne State University · Sites in United States
Ages 16–20
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 62 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 63 across the 203 observational. Of the 1,118 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
University of North Carolina, Chapel Hill has 9 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
115 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 115 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin. This study will learn if a three-stage CGM integration program ("intervention") that includes sessions focused on CGM technology skills, data skills, and lifestyle skills impacts CGM wear-time, glycemic metrics, and participant-reported outcomes, compared to two standard CGM training approaches ("comparators").
Following a screening visit and baseline data collection, participants will be randomized to either the intervention or one of the two comparator arms for 6 weeks. The intervention involves three educational sessions over 4 weeks. The first session will be in-person and subsequent sessions will be virtual. Participants in the intervention may receive 1-2 additional individualized training sessions to review CGM skills. The first comparator (Comparator 1) will receive a one-time clinic-based CGM training. The second comparator (Comparator 2) will be provided with a comprehensive informational pamphlet about CGM. All participants will complete outcomes data collection at 6 weeks.
The study will also explore participant experiences through a series of semi-structured interviews with a subset of purposively selected participants and their care partners to identify opportunities for scaling the intervention to a broader population. An extension phase of the study will evaluate long-term CGM use and associated outcomes 3- and 6-months post-intervention.
Lastly, we will run an additional small sub-study where consented care partners of participants will attend the intervention or comparator sessions alongside the study participant and provide care partner-specific data.
This study will assess the preliminary effectiveness of a continuous glucose monitor (CGM) integration program ("intervention") in a 6-week randomized pilot study among 144 older adults with diabetes using insulin at least once daily. The CGM integration program (48 participants) will be compared to two versions of usual care: 1) one-time clinic-based CGM training (Comparator 1; 48 participants) and 2) self-directed CGM training (Comparator 2; 48 participants). Following a screening visit and baseline data collection, participants will be randomized to one of the three groups in a 1:1:1 ratio by computer-generated sequence. All participants will be provided with 6-week supply of unblinded CGM sensors.
Participants who are randomized to the intervention group will attend three closed group sessions over 4 weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be held virtually and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be held virtually and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.
Participants randomized to the one-time clinic-based CGM training group (Comparator 1) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Participants randomized to the self-directed CGM training (Comparator 2) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.
At the end of the 6-week trial, all participants will provide primary endpoint data related to continuous wear-time. In addition, secondary patient-reported outcomes and glycemic metrics will be assessed, including use of the CGM device at 6 weeks. We will conduct semi-structured interviews with a subset of purposively sampled participants (up to 20) and their care partners (up to 10) after their final endpoint visit to probe effective aspects of the intervention, challenges, struggles, and needs that were not addressed by the intervention, and strategies to improve the accessibility, acceptability, and effectiveness of the intervention for future older adults.
We will conduct an extension study in which we evaluate the following metrics at 3- and 6-months post-intervention: 1) CGM prescribing patterns post-study, including the proportion of participants with a CGM order at 3 and 6 months after study endpoint; 2) Clinical and patient-reported outcomes, such as glycemic indicators, severe hypoglycemia, device satisfaction (if applicable), barriers to sustained CGM access, integration of CGM into care and self-management, and unmet needs; 3) provider documentation of clinical rationale, perceived benefits, and barriers to CGM use across diverse care settings (internal medicine, family medicine, geriatrics, endocrinology).
Lastly, this study will involve a care partner sub-study. The aim of the care partner sub-study is to understand how the intervention improves or changes the knowledge and attitudes around CGM and diabetes management in care partners of older adults with diabetes. Consented care partners will be invited to attend any session their partner participant is assigned to. Care partners will be asked to complete care partner-specific questionnaires at baseline, at the end of the 6-week trial, and at 3- and 6-months post-intervention.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Participant Inclusion Criteria:
Participant Exclusion Criteria:
Care Partner Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three-stage CGM integration program
Behavioral: Three-stage CGM integration program
One-time clinic-based CGM training
Behavioral: One-time clinic-based CGM training
Self-directed CGM training
Behavioral: Self-directed CGM training
Participants (and their consented care partner, if applicable) who are randomized to the intervention group will attend three closed group sessions over four weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be hybrid and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be hybrid and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.
Participants (and their consented care partner, if applicable) randomized to the one-time clinic-based CGM training group (Comparator A) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.
Participants randomized to the self-directed CGM training (Comparator B) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Consented care partners will not be directly involved, as there is no session visit to attend.
CGM Wear Time
CGM wear time will be calculated as the percentage of time that the sensor is in use and providing data, relative to the total time it could have been worn, with a total of 6-weeks of total possible wear during the active intervention period.
Time frame: Over 6 Weeks
CGM Use at 6 Weeks
CGM use will be determined as a yes/no binary response as to whether the study participant is wearing a CGM at the 6-week endpoint of the study intervention.
Time frame: Week 6
Change in Core Diabetes Distress using the Type 1 Diabetes Distress Assessment System (T1-DDAS) Core Score
The T1-DDAS will be administered to participants with Type 1 Diabetes. Self-reported core diabetes distress will be measured using the 30-item Type 1 Diabetes Distress Assessment System (T1-DDAS) Core Score. The scale yields a core score that is the average of all core questions (first 8 items) responses rated on a 5-point Likert scale for all 8 items, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher distress. A score \>= 2.0 is considered clinically significant diabetes distress.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Core Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score
The T2-DDAS will be administered to participants with Type 2 Diabetes. Self-reported core diabetes distress will be measured using the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score. The scale yields a core score that is the average of all core questions (first 8 items) responses rated on a 5-point Likert scale for all 8 items, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher distress. A score \>= 2.0 is considered clinically significant diabetes distress.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Sources of Diabetes Distress using the Type 1 Diabetes Distress Assessment System (T1-DDAS) Source Score
The T1-DDAS will be administered to participants with Type 1 Diabetes. Self-reported sources of diabetes distress will be measured using the 30-item Type 1 Diabetes Distress Assessment System (T1-DDAS) source scale. Responses are rated on a 5-point Likert scale, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher impact that the source is likely to have in contributing to diabetes distress.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Sources of Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Source Score
The T2-DDAS will be administered to participants with Type 2 Diabetes. Self-reported sources of diabetes distress will be measured using the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) source scale. Responses are rated on a 5-point Likert scale, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher impact that the source is likely to have in contributing to diabetes distress.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Impact of Diabetes Quality of Life-Brief Clinical Inventory (DQOL) Score
Self-reported DQOL 15-item survey will be measured. Responses are rated on 5-point Likert scale. 7 questions ask about the frequency of negative impacts of diabetes or diabetes treatment and are scored from 1 (Never) to 5 (All the Time). 8 questions ask about satisfaction with treatment and quality of life and are scored from 1 (Very Satisfied) to 5 (Very Dissatisfied). Scoring is done by adding the numeric responses to the 15 questions, and can range from 15-75, with a higher score indicating a higher problem frequency or more dissatisfaction.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Self Care Inventory-Revised Version (SCI-R) Score
Self-reported SCI-R 15-item survey will be measured. Responses are rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). For scoring, items are averaged and converted to a 0- to 100-point scale. Items that are not rated (or not applicable) are not included in the scoring. Higher scores indicate a better self-care.
Time frame: Baseline, Week 6
Change in Glucose Monitoring System Satisfaction Survey (GMSS) Type 1 Diabetes version Score
The GMSS Type 1 Diabetes version will only be administered to participants with Type 1 Diabetes. Self-reported glucose monitoring system satisfaction will be measured using the 15-item questionnaire. Responses are rated on a 5-point Likert scale with responses ranging from 1 (strongly disagree) to 5 (strongly agree). Scoring is done by calculating the mean score across responses. Certain items need to be reverse coded. A higher total score indicates greater satisfaction.
Time frame: Baseline, Week 6
Change in Glucose Monitoring System Satisfaction Survey (GMSS) Type 2 Diabetes version Score
The GMSS Type 2 Diabetes version will only be administered to participants with Type 2 Diabetes. Self-reported glucose monitoring system satisfaction will be measured using the 15-item questionnaire. Responses are rated on a 5-point Likert scale with responses ranging from 1 (strongly disagree) to 5 (strongly agree). Scoring is done by calculating the mean score across responses. Certain items need to be reverse coded. A higher total score indicates greater satisfaction.
Time frame: Baseline, Week 6
Change in Benefits of CGM (BenCGM) Score
Self-reported BenCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items using a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A higher mean score indicates higher perceived benefit of continuous glucose monitor (CGM).
Time frame: Baseline, Week 2, Week 4, Week 6, Month 3, Month 6
Change in Burdens of CGM (BurCGM) Score
Self-reported BurCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items based on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A higher mean score indicates higher perceived barriers of continuous glucose monitor (CGM).
Time frame: Baseline, Week 2, Week 4, Week 6, Month 3, Month 6
Change in Opinions and Beliefs about CGM Technology [Investigator-written]
Investigator-written items will assess participant opinions and beliefs about using CGM technology, with Likert scale responses to statements ranging from 1 (strongly disagree) to 6 (strongly agree). Change across each item will be calculated at key intervention milestones and used to understand efficacy of the intervention, with higher scores equating to higher confidence in CGM use and application.
Time frame: Week 2, Week 4, Week 6, Month 3, Month 6
Change in sleep quality affected by CGM [Investigator-written]
Investigator-written items to assess impact of CGM on sleep. Responses about sleep quality and impact will be ranked and assessed individually per item, with higher ranked responses indicating worsened impacts on sleep.
Time frame: Week 2, Week 4, Week 6, Month 3, Month 6
Change in quality of life affected by CGM [Investigator-written]
Investigator-written open-ended questions will explore impacts of participant CGM use on daily life. Responses will be thematically coded with standard qualitative data analysis methods.
Time frame: Week 2, Week 4, Week 6, Month 3, Month 6
Change in CGM satisfaction (CGM-SAT) Score
Impact of CGM intervention on CGM satisfaction will be reported at endpoint after the intervention (week 6) and at month 3 and month 6 if participant is using personal CGM at month 3 and month 6. Self-reported CGM-SAT 44-item survey will be measured. Responses are on a 5-point Likert scale with responses ranges from 1 (agree strongly) to 5 (disagree strongly). After reverse scoring some items, the mean is calculated with higher mean scores reflecting greater satisfaction with CGM. This scale also includes two open-ended questions that will be evaluated using qualitative research methods.
Time frame: Week 6, Month 3, Month 6
Change in Hypoglycemia Fear (Hypoglycemia Fear Survey; Worry Subscale, HFS-II W) Score
Self-reported HFS-II W 18-item survey will be measured. The scale is a 5-point Likert scale with responses ranging from 0 (never) to 4 (almost always). A score of 3 or higher on any of the 18 items indicates fear of hypoglycemia. Higher average scores indicate higher fear of hypoglycemia.
Time frame: Baseline, Week 6
Change in Clarke Score (Hypoglycemia Unawareness)
Self-reported Clarke Score 8-item survey will be measured. Each answer correlates with a rating of A (aware) or R (reduced). 4 or more R responses suggest reduced hypoglycemia awareness. 3 responses suggest indeterminant hypoglycemia awareness. 2 or fewer R responses suggest hypoglycemia awareness.
Time frame: Baseline, Week 6
Change in Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1) Score
Likert-type scale questions ranging from 1 (extremely unlikely) to 7 (extremely likely) for likelihood that each of the items would keep you from practicing regular physical activity during the next 6 months. Responses across 12-items are averaged, with lower average scores indicating a low level of perceived barriers to physical activity.
Time frame: Baseline, Week 6
Change in Healthy Eating Index (HEI) Score based on average intake across two 24-hour recalls
Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24)) per timepoint. Healthy Eating Index (HEI) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating from a select list of healthy food categories. The scores range from 0 to 100. An ideal overall Healthy Eating Index score of 100 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).
Time frame: Baseline, Week 6
Change in carbohydrate intake based on average intake across two 24-hour recalls
Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24)) per timepoint. Carbohydrate intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.
Time frame: Baseline, Week 6
Change in protein intake based on average intake across two 24-hour recalls
Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool; ASA24) per timepoint. Protein intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.
Time frame: Baseline, Week 6
Change in fat intake based on average intake across two 24-hour recalls
Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool; ASA24) per timepoint. Fat intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.
Time frame: Baseline, Week 6
Change in General Self-Efficacy Scale (GSE) Score
Self-reported General Self-Efficacy Scale (GSE) will be measured. Participants will be Likert-type scale questions ranging from Not at all true (1), Hardly true (2), Moderately true (3), Exactly true (4). The total score is calculated by finding the sum of all items. For the GSE, the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.
Time frame: Baseline, Week 6
Change in Hemoglobin A1c (HbA1c)
HbA1c (%) reflects average glucose over the past 2-3 months. Value will be assessed by standardized laboratory assay at baseline and Month 3.
Time frame: Baseline, Month 3
Change in Percentage of Time in Range (TIR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Baseline, Week 6
Change in Percentage of Time Below Range (TBR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Baseline, Week 6
Change in Percentage of Time Above Range (TAR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Baseline, Week 6
Change in Percentage of Glycemic Variability
When using the blinded continuous glucose monitors (CGM), glycemic variability will be assessed using the coefficient of variation (%CV) using 7-14 days of retrospective data at each time-point.
Time frame: Baseline, Week 6
Change in Percentage of Time in Range (TIR)
If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Month 3, Month 6
Change in Percentage of Time Below Range (TBR)
If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Month 3, Month 6
Change in Percentage of Time Above Range (TAR)
If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.
Time frame: Month 3, Month 6
Change in Percentage of Glycemic Variability
If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). Glycemic variability will be assessed using the coefficient of variation (%CV) using 7-14 days of retrospective data at each time-point.
Time frame: Month 3, Month 6
Change in care partner Opinions and Beliefs about CGM Technology [Investigator-written]
Investigator-written items will assess opinions and beliefs of care partners about participant's use of CGM technology, with Likert scale responses to statements ranging from 1 (strongly disagree) to 6 (strongly agree). Change across each item will be calculated at key intervention milestones and used to understand efficacy of the intervention, with higher scores equating to higher confidence in CGM use and application.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in care partner sleep quality affected by CGM [Investigator-written]
Investigator-written items to assess impact of participant CGM use on care partner's sleep. Responses about sleep quality and impact will be ranked and assessed individually per item, with higher ranked responses indicating worsened impacts on sleep.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in care partner quality of life affected by CGM [Investigator-written]
Investigator-written open-ended questions will explore impacts of participant's CGM use on care partner's daily life. Responses will be thematically coded with standard qualitative data analysis methods.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Care Partner Diabetes Distress (Partner DDS) Score
Care partners of participants will be offered to complete the 21-item Partner Diabetes Distress (Partner DDS) questionnaire. The survey yields a mean score based on a 4-point Likert scale with responses ranging from 0 (not at all) to 4 (a great deal). Total score is calculated as the mean of the 21 items. Mean item score of 0-1.9 is considered little or no distress, between 2-2.9 is considered moderate distress, and \>=3 is considered high distress.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in Care Partner Hypoglycemia Confidence Scale (Partner-HCS) Score
Care partners of participants will be offered to complete the 12-item Partner Hypoglycemia Confidence Scale (Partner-HCS). The survey yields a mean score based on a 4-point Likert scale with responses ranging from 1 (not confident at all) to 4 (very confident). Total score is calculated as the mean of the 12 items. Higher mean score reflects higher partner hypoglycemia confidence and lower mean score reflects lower partner hypoglycemia confidence.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in DAWN Family Experience of Patient Involvement (DFEPI) Score
Care partners of participants will be offered to complete the 4-item DAWN Family Experience of Patient Involvement (DFEPI). Two questions use a Likert scale with responses ranging from 1 (never) to 5 (always) to assess communication of support needs. Higher composite scores indicate a higher level of communication received about needs for support. Two questions use a Likert scale with responses ranging from 1 (much less involved) to 5 (much more involved) to assess preferred level of involvement of family member. Higher composite scores indicate a care partner's higher desire for involvement in the participant's diabetes care.
Time frame: Baseline, Week 6, Month 3, Month 6
Change in DAWN Impact of Diabetes Profile - Family Members (DIDP-FM) Score
Care partners of participants will be offered to complete the 7-item DAWN Impact of Diabetes Profile - Family Members (DIDP-FM). The survey yields a composite score based on a 7-point Likert scale with responses ranging from 1 (very negative impact) to 7 (very positive impact). N/A responses (8) are treated as missing. A composite scale score can be derived by taking the sum of items divided by the number of complete responses (i.e. not missing or N/A). Lower scale scores indicate greater negative impact and higher scale scores indicate greater positive impact of diabetes on a family member's life.
Time frame: Baseline, Week 6, Month 3, Month 6
Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 6 to 18 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Time frame: Beginning 6 and continuing for 18 months following publication
Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 19 months is close to that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2028 → Mar 2028, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →